SEC Form 4 · accession 0001209191-17-028260
Phio Pharmaceuticals Corp. · PHIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gerrit Dispersyn
Officer — Chief Development Officer
Period of report
Apr 24, 2017
Accepted (ET)
Apr 26, 2017 · 6:36 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001533040
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $0.65 | Apr 24, 2017 | A | 95,000 | A | — | Apr 24, 2027 | Common stock | 95,000 | 95,000 | D |
Explanation of responses
- F1The stock option vests in equal monthly installments over four years beginning on the first monthly anniversary of the grant date.